PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support

PeerCurrent

PcPeerCurrent

Your Feed AI Summary Saved Board Expert Discussion This Week in Your Field

Follows Journals Trials Guidelines Markets

Set your cadence Alerts Settings Help

Back to follows

Researcher

Aria A. Argus

Northwestern University

1 development in the corpus

Following this puts new work involving it at the top of your briefing, with a note saying why it is there. Links are taken from the source record, never inferred.

For You Latest Breakthroughs Trials Reviews Guidelines

Latest

Everything in the corpus, newest first.

SEP 7, 2026 · JOURNAL ARTICLE

Exploiting Acquired Drug Resistance in Pancreatic Cancer through Selective Covalent Targeting of MAP2K4/7

Acs Chemical Biology

Mechanistic preclinical study proposing a resistance-escape strategy in cell models; no clinical data, no human subjects, and no comparative efficacy trial to support practice change.

Hypothesis-GeneratingKarl A. Scheidt Aria A. Argus Gina M. Connors

Study details

DesignPreclinical in vitro mechanistic study

InterventionSelective MAP2K4 inhibitor, MAP2K7 inhibito…

ComparatorKRAS inhibitor monotherapy; KRASG12D inhibi…

PeerCurrent.com|Stay current with the people and research shaping what comes next.

About Privacy Terms Support